Sciwind begins Phase 3 trial of ecnoglutide in obesity with knee osteoarthritis

Hangzhou Sciwind Biosciences has started enrolling a Phase 3 study of its drug ecnoglutide in people who have both obesity and knee osteoarthritis, moving the trial from "not yet recruiting" to "recruiting" ^[1]. The change was recorded by a service that snapshots ClinicalTrials.gov six times a day and keeps the previous value, because the registry itself overwrites a record without leaving a public history of what it used to say ^[1].

Ecnoglutide is not a new molecule. China's drug regulator approved the injection for type 2 diabetes in January 2026 and for chronic weight management in March 2026 ^[2]. In February 2026, Pfizer struck a deal worth up to $495 million for Chinese commercialization rights ^[2]. A head-to-head trial presented in June 2026 showed ecnoglutide produced 35% greater weight loss than semaglutide, the molecule sold in the US as Ozempic, Wegovy and Rybelsus ^[2].

The osteoarthritis indication puts Sciwind on ground Eli Lilly has already claimed. Retatrutide, Lilly's triple agonist, delivered its first successful Phase 3 readout in the TRIUMPH-4 knee osteoarthritis trial in December 2025 ^[2]. Lilly then reported pivotal Phase 3 obesity results from TRIUMPH-1 in May 2026 — up to 30.3% average body weight loss at two years, the highest reported to date among injectable obesity drugs in late-stage trials ^[2].

What the new ecnoglutide trial will measure, how many participants it will enroll, how long it will run and when it is expected to finish have not been reported ^[1]. Whether Sciwind plans to seek US approval of ecnoglutide for osteoarthritis, or for any other use, has not been disclosed ^[2].

Why it matters for patients

Obesity and knee osteoarthritis commonly occur together, and knee pain is a frequent reason people who carry extra weight struggle to exercise. The ongoing trials — TRIUMPH-4 and the new ecnoglutide study — are testing whether weight loss from these drugs also reduces joint pain and improves physical function. That is a different question from how many pounds come off, and it is generally slower to answer because participants are followed for a year or more.

For anyone in the US, ecnoglutide is not an option right now. It is approved in China for type 2 diabetes and chronic weight management, and Pfizer holds its Chinese commercialization rights ^[2]. No US approval or FDA submission for the drug has been announced in these reports. Retatrutide is also not yet approved, though Lilly has confirmed it created an expanded access program letting physicians request the drug for eligible patients before FDA action ^[2].

The evidence base for a knee osteoarthritis claim is still thin. The 35% greater weight loss versus semaglutide came from a head-to-head trial in a different population, presented in June 2026 ^[2]. Results in a knee osteoarthritis group, whose members are often older and less mobile, can differ from results in a general obesity group.

What happens next

Lilly has said seven more Phase 3 readouts for retatrutide are expected in 2026 ^[2]. Those results are likely to set the benchmark Sciwind's osteoarthritis trial will be measured against, and they will also shape how insurers and clinicians view a weight-loss drug marketed for a joint condition.

For the ecnoglutide trial, the recruiting status is the only milestone reported so far ^[1]. No enrollment target, no primary endpoint, no estimated completion date and no data-readout timing have been disclosed ^[1]. The trial's registry record will be the place to watch, since each change — a date moving, a status flipping, an enrollment number being resized — is the kind of update that is otherwise erased the day after it happens ^[1].